How to Compare CDMOs for Your Manufacturing Program

Before comparing CDMOs, define what the program actually requires.

That may include the modality, development stage, required manufacturing capabilities, regulatory requirements, production or batch scale, preferred geography, anticipated project kickoff, budget, and any additional support services the sponsor expects from the manufacturing partner.

This matters because the same CDMO can look very different depending on the project.

A manufacturer that appears well aligned with a Phase I biologics program may not be the right fit for a commercial small-molecule program. A facility with the right technical capabilities may still be impractical if its scale, timing, geography, or project model does not align with the sponsor's needs.

CDMO comparison becomes much more useful once the comparison criteria are tied to an actual program.

Not every comparison criterion should be treated the same way.

Some requirements may determine whether a CDMO is technically relevant at all. Others help prioritize manufacturers that already appear capable of supporting the project.

For example, required modality, manufacturing capability, regulatory expectations, or partner-fit requirements may be fundamental to whether a company belongs on the shortlist.

Budget, geography, timing, development stage, batch size, and support-service preferences may help distinguish between otherwise relevant options.

This distinction prevents a common sourcing problem: giving every criterion equal importance even when some factors matter much more to the program than others.

PCN allows users to adjust project priorities including batch size, development stage, project kickoff, budget, geography, and support services, then recalculate results around those priorities.

One of the easiest mistakes in CDMO selection is evaluating only the company name.

Many CDMOs operate multiple manufacturing facilities. Those facilities may support different modalities, technologies, production scales, equipment, regulatory markets, or stages of development.

So the better question is often not:

"Does this CDMO offer the service?"

It is:

"Which facility appears relevant to this manufacturing program?"

Where available, PCN includes facility-level information so sponsors can investigate the manufacturing site behind the parent company.

That can make a significant difference when comparing large CDMO organizations with multiple locations.

A company's website may say it supports biologics, small molecules, cell and gene therapy, fill finish, analytical development, or another broad category.

That is useful for discovery, but it is usually not enough for a sourcing decision.

Sponsors should look more closely at the specific CDMO manufacturing services and technical capabilities required by the program.

Depending on the project, that could include process development, formulation, analytical support, GMP manufacturing, fill finish, technology transfer, scale-up, or other specialized manufacturing capabilities.

The goal is not to find the CDMO with the longest capability list.

The goal is to determine whether the capabilities that matter to your program are actually available in a relevant manufacturing environment.

Manufacturing scale can eliminate an otherwise attractive CDMO surprisingly quickly.

A company may work in the correct modality but primarily support a different project scale. Another may have technically relevant capabilities but not the manufacturing equipment required for the sponsor's process.

When structured information is available, compare details such as production scale, batch size, manufacturing equipment, and facility capabilities.

These factors help move the comparison from a company-level marketing claim to a more practical assessment of whether a particular site may be suitable for the program.

Regulatory history should be part of CDMO comparison, but it needs context.

PCN provides access to FDA Form 483 information so sponsors can incorporate facility-level regulatory information into preliminary diligence.

A Form FDA 483 should not automatically be interpreted as proof that a manufacturer is unsuitable. Regulatory information should be considered alongside the observations involved, the facility, subsequent responses or actions, technical fit, and the sponsor's own quality and vendor-qualification process.

The purpose of bringing this information into CDMO sourcing is not to create a simplistic good-or-bad rating.

It is to help teams identify what may deserve closer review before advancing a manufacturing partner.

Technical capability is only part of the decision.

A manufacturing partner may appear technically suitable and still be difficult to work with for a particular program because of project timing, geography, budget expectations, development-stage focus, support needs, or sponsor profile.

Useful CDMO comparison therefore includes both technical and operational considerations.

For many biotech teams, the right question is not simply:

"Can this manufacturer make the product?"

It is also:

"Does this manufacturer appear structured to support a program like ours?"

That distinction becomes particularly important for early-stage and emerging biotech companies.

PCN provides a Match % to help sponsors understand how closely a potential manufacturing partner aligns with a particular program.

A manufacturer with a strong match for one program may have a much lower match for another because the requirements are different.

That is intentional.

CDMO comparison should be project-specific rather than based on a universal ranking of manufacturers.

Users can also adjust project priorities and recalculate results as requirements change or the sourcing strategy becomes more defined.

A useful shortlist should not simply contain three or five company names.

For each CDMO, the sponsor should be able to explain why the company is being considered.

That explanation may include:

The result is a shortlist based on evidence and project requirements rather than name recognition alone.

Many teams start contacting manufacturers before the shortlist is well defined.

That can lead to unnecessary outreach, repeated explanations of the project, and conversations with companies that were unlikely to fit in the first place.

A more efficient sequence is:

1. Define the program→
2. identify potential matches→
3. compare fit→
4. conduct preliminary diligence→
5. contact manufacturers worth advancing

PCN supports that workflow by allowing sponsors to move from structured requirements into matching, comparison, preliminary diligence, and structured introduction requests.

You do not need to start from zero to use a structured comparison process.

A sponsor may already have CDMO candidates from referrals, a consultant, previous relationships, conferences, LinkedIn, internal research, or a CDMO directory.

Those names can still be evaluated against the actual requirements of the program.

This can be especially useful when a shortlist is based heavily on reputation or network recommendations and the team wants a more systematic second look.

Pharma Connect Navigator is a project-based CDMO search, sourcing, matching, preliminary diligence, and sponsor-CDMO connection platform.

Rather than presenting an undifferentiated list of manufacturers, PCN starts with the manufacturing program and uses structured CDMO and facility information to help sponsors identify and compare potential partners.

Sponsors can investigate project fit, facilities, manufacturing capabilities, equipment, FDA 483 context, and other available information before deciding which manufacturers are worth advancing.

Once a potential partner appears relevant, the sponsor can request a structured introduction and allow the CDMO to confirm whether the project may fit.

Later in the process, a CDMO site visit checklist can help structure an in-person facility review, and the guide on how to choose a CDMO covers final selection criteria.

It is designed to make the early sourcing and evaluation process more structured.